此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)

2026年6月19日 更新者:Maciej Harat、Prof. Franciszek Lukaszczyk Memorial Oncology Center

Tumor Treating Fields (TTFields) Concomitant With Stereotactic Radiosurgery Based on FET-PET vs TTFields Alone for the Treatment of Recurrent, Glioblastoma (Tarrget 2.0)

This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.

Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation.

The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.

研究概览

详细说明

Glioblastoma is the most common malignant primary brain tumor in adults and remains associated with poor prognosis despite multimodal treatment. There is currently no established standard therapy for recurrent glioblastoma, and outcomes remain unsatisfactory.

Tumor Treating Fields (TTFields) are low-intensity, intermediate-frequency alternating electric fields that disrupt mitosis and inhibit tumor growth. TTFields have demonstrated efficacy in recurrent and newly diagnosed glioblastoma with minimal systemic toxicity.

Stereotactic radiosurgery (SRS) is an established local treatment option for selected patients with recurrent glioblastoma. However, MRI-based target delineation may underestimate the true extent of infiltrative tumor growth. FET-PET imaging provides improved visualization of metabolically active tumor tissue and may improve treatment precision.

Preclinical studies suggest synergistic effects between TTFields and radiation therapy through increased radiosensitivity and modulation of DNA repair mechanisms. Additional immunomodulatory effects may further enhance treatment efficacy.

This prospective randomized single-center study will compare TTFields combined with FET-PET-guided stereotactic radiosurgery versus TTFields alone in patients with recurrent IDH-wildtype glioblastoma. The primary objective is to determine whether combined treatment improves the one-year overall survival rate.

研究类型

介入性

注册 (估计的)

92

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Agnieszka Rydzewska, Study Coordinator
  • 电话号码:+48 52 3743082
  • 邮箱:glejak@co.bydgoszcz.pl

学习地点

      • Bydgoszcz、波兰、85-796
        • 招聘中
        • Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥18 years
  • Karnofsky Performance Status ≥70
  • Histologically confirmed IDH-wildtype glioblastoma
  • First, second, or third recurrence
  • Radiological recurrence according to RANO 2.0 criteria
  • Prior radiotherapy and temozolomide treatment
  • At least 6 months since completion of previous radiotherapy
  • Contrast-enhancing recurrent lesion visible on MRI
  • Maximum recurrent lesion diameter ≤5 cm
  • Available molecular profile including IDH and MGMT status
  • Adequate hematologic, renal, and hepatic function
  • Written informed consent

Exclusion Criteria:

  • Previous bevacizumab treatment
  • Planned chemotherapy or targeted therapy after study intervention
  • Previous stereotactic re-irradiation within the planned treatment field
  • More than three recurrences
  • Significant psychiatric disorders
  • Significant unrelated neurological disease
  • Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device
  • Pregnancy or breastfeeding
  • Active intracranial hemorrhage
  • Uncontrolled hypertension
  • Severe renal dysfunction
  • Participation in another interventional study likely to interfere with this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:TTFields Plus FET-PET-Guided Stereotactic Radiosurgery
Participants receive Tumor Treating Fields (TTFields) therapy combined with FET-PET-guided stereotactic radiosurgery (SRS) for recurrent IDH-wildtype glioblastoma. TTFields treatment is administered for four months. Stereotactic radiosurgery is delivered within 14 days after initiation of TTFields according to protocol-defined target volumes based on MRI and FET-PET imaging.
Tumor Treating Fields (TTFields) therapy delivered using alternating electric fields through transducer arrays placed on the scalp. Treatment is administered continuously according to the study protocol for patients with recurrent IDH-wildtype glioblastoma.
Stereotactic radiosurgery planned using MRI and FET-PET imaging for treatment of recurrent IDH-wildtype glioblastoma. Radiosurgery is delivered within 14 days after initiation of TTFields according to protocol-defined target volumes.
有源比较器:TTFields Alone
Participants receive Tumor Treating Fields (TTFields) therapy alone for recurrent IDH-wildtype glioblastoma according to standard clinical practice. TTFields treatment is administered for four months.
Tumor Treating Fields (TTFields) therapy delivered using alternating electric fields through transducer arrays placed on the scalp. Treatment is administered continuously according to the study protocol for patients with recurrent IDH-wildtype glioblastoma.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
One-Year Overall Survival Rate
大体时间:12 months after randomization
Proportion of participants alive 12 months after randomization
12 months after randomization

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:From randomization until death from any cause, up to 81 months
Overall survival is defined as the time from randomization to death from any cause. Participants who are alive at the time of analysis will be censored at the date of last contact. Median overall survival will be estimated using the Kaplan-Meier method.
From randomization until death from any cause, up to 81 months
Progression-Free Survival (PFS)
大体时间:Up to 12 months after randomization
Progression-free survival is defined as the time from randomization to radiographic disease progression according to RANO 2.0 criteria or death from any cause, whichever occurs first. Participants without an event will be censored at the date of last disease assessment. Median, 6-month, and 12-month progression-free survival rates will be estimated.
Up to 12 months after randomization
Objective Response Rate (ORR)
大体时间:Up to 12 months after randomization
Objective response rate is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RANO 2.0 criteria within 12 months after randomization. Best overall response will be determined using serial MRI assessments.
Up to 12 months after randomization
Radiation-Induced Contrast Enhancement (RICE)
大体时间:Up to 12 months after randomization
Radiation-induced contrast enhancement is defined as new or increasing contrast enhancement observed on follow-up MRI that subsequently remains stable or resolves without evidence of tumor progression. The incidence of radiation-induced contrast enhancement (RICE) will be assessed and compared between study groups.
Up to 12 months after randomization
Treatment-Related Adverse Events
大体时间:From randomization through 12 months after randomization
Treatment-related adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. The proportion of participants experiencing grade 3 or higher treatment-related adverse events will be compared between treatment groups.
From randomization through 12 months after randomization
Patterns of Failure
大体时间:Up to 12 months after randomization
Patterns of failure will be evaluated based on the location of disease progression relative to the baseline recurrent tumor volume identified on screening MRI and treatment planning imaging. Disease progression will be classified as local, marginal, or distant.
Up to 12 months after randomization
Molecular Predictors of overall survival
大体时间:Up to 81 months after randomization
Associations between molecular tumor characteristics, including MGMT promoter methylation status and other available molecular markers, and treatment outcomes will be evaluated to identify potential predictors of overall survival
Up to 81 months after randomization
Corticosteroid Requirements
大体时间:From randomization until disease progression, up to 12 months after randomization
Corticosteroid requirements will be assessed as the cumulative and daily corticosteroid dose administered from randomization until disease progression. Changes in corticosteroid use over time will be compared between treatment groups.
From randomization until disease progression, up to 12 months after randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月30日

初级完成 (估计的)

2030年6月1日

研究完成 (估计的)

2032年6月1日

研究注册日期

首次提交

2026年6月10日

首先提交符合 QC 标准的

2026年6月19日

首次发布 (实际的)

2026年6月25日

研究记录更新

最后更新发布 (实际的)

2026年6月25日

上次提交的符合 QC 标准的更新

2026年6月19日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

Individual participant data that underlie the results reported in publications may be made available upon reasonable request to the Principal Investigator, following approval of a research proposal and execution of a data sharing agreement

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅